focus -WSS

focus

author：comprehensive 2025-09-06 02:16:25 - browse：48

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

knowledge

WSS

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Meta looks to target Twitter with a rival app called Threads

Australia's humpback populations rebound raising hopes of marine scientists

AI for drug discovery: Experts on separating hype from reality

RaDonda Vaught case: a double standard for nurses, physicians

GSK’s asthma push continues as drug succeeds in Phase 3 trials

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

Can food be medicine? And other questions about a new push

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Peter Hotez and the public health issue of online harassment

Make 'food is medicine' a key part of White House nutrition meeting

Medicare proposal to cover medical devices draws a mixed reaction

Connecting traumatic brain injury and domestic violence

The high cost of giving birth even with insurance

AI for drug discovery: Experts on separating hype from reality

Wikipedia

As health system earnings go up, health insurance stocks go down

AltruBio raises $225 million to develop ulcerative colitis drug

BIO to announce reorganization, senior leaders expected to depart

Bacterial infection may be ‘key event’ in endometriosis, study says

PBM executives asked to testify by House panel

Doctor appointment wait times are getting worse

hotspot

leisure time

knowledge

focus